Orchard Therapeutics, a commercial and clinical-stage company, has opened a new US office located in Boston’s Seaport District, building upon the company’s footprint in London as well as Foster City and Menlo Park, California.
Boston
“The opening of our Boston office represents a significant milestone in the growth and global expansion of Orchard Therapeutics” commented Mark Rothera, president and CEO of Orchard. “We look forward to joining the thriving biotechnology and academic communities in Boston, Cambridge and the surrounding area. The area has a deep pool of talent with complementary capabilities to help us realize our vision of becoming a global, fully integrated company transforming the lives of patients with rare diseases.”
The company’s portfolio of autologous ex vivo gene therapy programmes include Strimvelis, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programmes in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), other clinical programmes in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.
Orchard’s most-advanced development candidate OTL-101 for ADA-SCID, is expected to progress to a BLA (biological licence application) with the FDA in 2018.